Impact of PSMA PET on Prostate Cancer Management

Adam B Weiner; Raag Agrawal; Luca F Valle; Ida Sonni; Amar U Kishan; Matthew B Rettig; Steven S Raman; Jeremie Calais; Paul C Boutros; Robert E Reiter

doi:10.1007/s11864-024-01181-9

Impact of PSMA PET on Prostate Cancer Management

Curr Treat Options Oncol. 2024 Feb;25(2):191-205. doi: 10.1007/s11864-024-01181-9. Epub 2024 Jan 25.

Authors

Adam B Weiner^{1

2}, Raag Agrawal^{3

4

5}, Luca F Valle^{6

7}, Ida Sonni^{8

9}, Amar U Kishan⁶, Matthew B Rettig^{10

11}, Steven S Raman⁸, Jeremie Calais¹², Paul C Boutros^{10

3

4

5}, Robert E Reiter^{10

5}

Affiliations

¹ Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. abweiner@mednet.ucla.edu.
² Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA. abweiner@mednet.ucla.edu.
³ Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA.
⁴ Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁵ Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.
⁶ Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁷ Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
⁸ Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁹ Department of Clinical and Experimental Medicine, University Magna Graecia, Catanzaro, Italy.
¹⁰ Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
¹¹ Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
¹² Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

Abstract

PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.

Keywords: Clinical decision-making; Drug therapy; Neoplasm staging; Positron-emission tomography; Prognosis; Prostatic neoplasms; Radiotherapy; Surgery; Theranostic nanomedicine.

Publication types

Review

MeSH terms

Antigens, Surface*
Humans
Male
Neoplasm Staging
Positron Emission Tomography Computed Tomography / methods
Prospective Studies
Prostate-Specific Antigen
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / therapy
Radiopharmaceuticals / therapeutic use

Substances

Antigens, Surface
Radiopharmaceuticals
Prostate-Specific Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding